Leaderboards/Renal and related cancers

Renal and related cancers

Last updated June 1, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Jian Zhou
Unknown
99
2
Michael A. Carducci
Johns Hopkins University
97
3
Amir Mortazavi
The Ohio State University
92
4
Zhenfa Zhang
Tianjin Medical University Cancer Institute and Hospital
92
5
Weiying Lin
Guangxi University
90
6
Eric Jonasch
The University of Texas MD Anderson Cancer Center
86
7
Hong C. Shen
Unknown
81
8
M. Dreyling
Ludwig-Maximilians-Universität München
75
9
Yong Ke
Zunyi Medical University
74
10
Peter J. Blankestijn
Utrecht University
73

Rising Stars Papers

Insufficient data

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Zheng Wang
Ministry of Education
99
2
Kelsey Natsuhara
University of California, San Francisco
85
3
Kim M. Pabst
West German Heart and Vascular Center Essen
85
4
Tyler K. T. Smith
Institute of Infection and Immunity
84
5
Ramaprasad Srinivasan
National Institutes of Health
82
6
Kartik Sehgal
Dana-Farber Cancer Institute
80
7
Haojie Dai
Nanjing Medical University
78
8
Hao Ning
Chongqing Medical University
77
9
James P Buteau
The University of Melbourne
75
10
Haiyan Weng
Sun Yat-sen University
73

Emerging Leaders Papers

Insufficient data

All-Time Leaders

The canon

All-Time Leaders Researchers

1
Mario Sznol
Yale Cancer Center
99
2
Chun Zhang
Union Hospital
98
3
Elżbieta Senkus
Gdańsk Medical University
97
4
Martin Reck
German Center for Lung Research
96
5
Gianluca Trobia
Ospedale Cannizzaro
87
6
Masatoshi Kudo
Kindai University
86
7
Dirk Arnold
Asklepios Klinik Altona
86
8
Jon M. Wigginton
Bristol-Myers Squibb (United States)
85
9
Karin Jordan
University Hospital Heidelberg
83
10
Rory Collins
University of Oxford
81

All-Time Leaders Papers

1
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
New England Journal of Medicine|2012
12.6k cit.
2
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
Gut|2019
714 cit.
3
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
JAMA Oncology|2019
630 cit.
4
PLX4032, a selective BRAF <sup>V600E</sup> kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF <sup>WT</sup> melanoma cells
Pigment Cell & Melanoma Research|2010
322 cit.
5
FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma
Hepatology|2012
153 cit.
6
Cold‐inducible <scp>RNA</scp>‐binding protein promotes the development of liver cancer
Cancer Science|2015
60 cit.
7
MiR-34a and miR-203 Inhibit Survivin Expression to Control Cell Proliferation and Survival in Human Osteosarcoma Cells
Journal of Cancer|2016
45 cit.
8
<scp>MDM</scp>2 is implicated in high‐glucose‐induced podocyte mitotic catastrophe <i>via</i> Notch1 signalling
Journal of Cellular and Molecular Medicine|2017
33 cit.
9
Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases
International Journal of Molecular Sciences|2022
28 cit.
10
MAD2B promotes podocyte injury through regulating Numb-dependent Notch 1 pathway in diabetic nephropathy
International Journal of Biological Sciences|2022
23 cit.

Reagents for Renal and related cancers

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Recommended

Best all-around

BioLegend

PE/Cyanine7 anti-OCT4 (OCT3)

Cited in 14 papers
#653717 (also 653718)
View Evidence →Abcam

Anti-Nanog antibody [RM1168]

Cited in 14 papers
#ab317506
View Evidence →Abcam

Anti-Oct4 antibody [EPR17929] - Low endotoxin, Azide free

Cited in 14 papers
#ab215386
View Evidence →

🌟 All-Time

Most validated

Agilent/Dako

Wilms Tumor Protein 1

Cited in 23 papers
#M3561
View Evidence →Santa Cruz Biotechnology

Oct3/4 Antibody (C-10)

Cited in 18 papers
#sc-5279
View Evidence →Proteintech

PAX8 antibody

Cited in 15 papers
#10336-1-AP$449
View Evidence →